CN1939290A - Medical usage of colchicine and its derivative - Google Patents
Medical usage of colchicine and its derivative Download PDFInfo
- Publication number
- CN1939290A CN1939290A CN 200510030151 CN200510030151A CN1939290A CN 1939290 A CN1939290 A CN 1939290A CN 200510030151 CN200510030151 CN 200510030151 CN 200510030151 A CN200510030151 A CN 200510030151A CN 1939290 A CN1939290 A CN 1939290A
- Authority
- CN
- China
- Prior art keywords
- colchicine
- derivant
- thrombosis
- blood
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 title claims abstract description 137
- 229960001338 colchicine Drugs 0.000 title claims description 65
- 201000010099 disease Diseases 0.000 claims abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
- 239000007924 injection Substances 0.000 claims description 36
- 238000002347 injection Methods 0.000 claims description 36
- 241001597008 Nomeidae Species 0.000 claims description 21
- 208000007536 Thrombosis Diseases 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 12
- 208000005189 Embolism Diseases 0.000 claims description 11
- 208000001435 Thromboembolism Diseases 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 3
- 206010051055 Deep vein thrombosis Diseases 0.000 claims description 2
- 206010047249 Venous thrombosis Diseases 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 229940107685 reopro Drugs 0.000 claims description 2
- 206010008132 Cerebral thrombosis Diseases 0.000 claims 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000003055 low molecular weight heparin Substances 0.000 claims 1
- 229940127215 low-molecular weight heparin Drugs 0.000 claims 1
- 206010014523 Embolism and thrombosis Diseases 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 42
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 38
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 37
- 229960000187 tissue plasminogen activator Drugs 0.000 description 36
- 210000002381 plasma Anatomy 0.000 description 30
- 210000004369 blood Anatomy 0.000 description 22
- 239000008280 blood Substances 0.000 description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 15
- 102000009123 Fibrin Human genes 0.000 description 13
- 108010073385 Fibrin Proteins 0.000 description 13
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 13
- 229950003499 fibrin Drugs 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 12
- 102000013566 Plasminogen Human genes 0.000 description 12
- 108010051456 Plasminogen Proteins 0.000 description 12
- 238000002372 labelling Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 238000003757 reverse transcription PCR Methods 0.000 description 10
- 239000012190 activator Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000000155 isotopic effect Effects 0.000 description 8
- 239000001509 sodium citrate Substances 0.000 description 8
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 208000006193 Pulmonary infarction Diseases 0.000 description 7
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 7
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 7
- 210000002889 endothelial cell Anatomy 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 239000003527 fibrinolytic agent Substances 0.000 description 7
- 230000007575 pulmonary infarction Effects 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 229960005356 urokinase Drugs 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 102000005686 Serum Globulins Human genes 0.000 description 6
- 108010045362 Serum Globulins Proteins 0.000 description 6
- 239000003146 anticoagulant agent Substances 0.000 description 6
- 230000003480 fibrinolytic effect Effects 0.000 description 6
- 238000011580 nude mouse model Methods 0.000 description 6
- 108090000190 Thrombin Proteins 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000002685 pulmonary effect Effects 0.000 description 5
- 229960004072 thrombin Drugs 0.000 description 5
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 4
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 4
- 108010049003 Fibrinogen Proteins 0.000 description 4
- 102000008946 Fibrinogen Human genes 0.000 description 4
- 108010088842 Fibrinolysin Proteins 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229960005052 demecolcine Drugs 0.000 description 4
- 229940012952 fibrinogen Drugs 0.000 description 4
- 210000004731 jugular vein Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000002537 thrombolytic effect Effects 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 101000801487 Mus musculus Tissue-type plasminogen activator Proteins 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 229940001501 fibrinolysin Drugs 0.000 description 3
- 230000020764 fibrinolysis Effects 0.000 description 3
- 229940106780 human fibrinogen Drugs 0.000 description 3
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 2
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000003725 endotheliocyte Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- JWDFWIZNGSOUGC-INIZCTEOSA-N n-[(7s)-10-amino-1,2,3-trimethoxy-9-oxo-6,7-dihydro-5h-benzo[a]heptalen-7-yl]acetamide Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(N)=CC=C1C1=C2C=C(OC)C(OC)=C1OC JWDFWIZNGSOUGC-INIZCTEOSA-N 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000013595 supernatant sample Substances 0.000 description 2
- YLWAQARRNQVEHD-PBZHRCKQSA-N tazettine Chemical compound O([C@]1(O)CN2C)CC3=CC=4OCOC=4C=C3[C@]31[C@@H]2C[C@H](OC)C=C3 YLWAQARRNQVEHD-PBZHRCKQSA-N 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- -1 COLC Chemical compound 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241000723375 Colchicum Species 0.000 description 1
- 241001507943 Cormus Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 241000234479 Narcissus Species 0.000 description 1
- 241001250596 Pleione Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000013674 S-100 Human genes 0.000 description 1
- 108700021018 S100 Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- XEEPVFFWNATEGX-IUHNQTRMSA-N Tazettadiol Natural products C1=C(CO)C([C@]23[C@H](O)CN(C)[C@H]2C[C@@H](C=C3)OC)=CC2=C1OCO2 XEEPVFFWNATEGX-IUHNQTRMSA-N 0.000 description 1
- 102000019400 Tissue-type plasminogen activator Human genes 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000001946 anti-microtubular Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002137 anti-vascular effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- XCXGMRBXICPEKF-UHFFFAOYSA-L disodium;dodecane;sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O.CCCCCCCCCCCC XCXGMRBXICPEKF-UHFFFAOYSA-L 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001723 fibrinogenic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000020971 positive regulation of blood coagulation Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- KLJOYDMUWKSYBP-SLEMLFNQSA-N pretazettine Natural products CO[C@H]1C[C@@H]2N(C)C[C@@H]3O[C@@H](O)c4cc5OCOc5cc4[C@]23C=C1 KLJOYDMUWKSYBP-SLEMLFNQSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001034 respiratory center Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- YLWAQARRNQVEHD-UHFFFAOYSA-N sekisanoline Natural products CN1CC2(O)OCC3=CC=4OCOC=4C=C3C32C1CC(OC)C=C3 YLWAQARRNQVEHD-UHFFFAOYSA-N 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A medical application of the colchicin and its derivatives in preventing and treating the diseases caused by intravascular thrombosis and embolism is disclosed.
Description
Technical field
The present invention relates to the medical usage of a kind of alkaloid and its derivant, more specifically refer to from the Colchicum plant, extract colchicine and its derivant.
Background technology
Colchicine (colchicine) has another name called Colchicine, COLC, Colchineos, Colcin, Colgout, Aquacolchin, NSC-757. are from Liliaceae Colchicum plant colchici cormus and seed etc. or from liliaceous plant, and a kind of alkaloid that extracts in Pseudobulbus Cremastrae Seu Pleiones and the Chinese narcissus is produced in Yunnan.Formal name used at school N-((7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo (a) heptalen-7-yl-acetamide, structural formula is C
22H
25NO
6, molecular weight is its chemical mechanism See Figure of 399.44Dolton:
Colchicine separated (Pelletier PS, Caventon J.Ann.Chim.Phys.1820 as far back as 1820; 14:69), be used to treat gout at first, after be found colchicine and can be combined in intracellular tubular proteins, suppress the mitosis of cell.After, it is found that colchicine can suppress the free of blood neutrophilic granulocyte, has the reaction of reducing inflammation curative effect.
Colchicine thirties is just as the instrument medicine of chromosome research.According to existing document description, colchicine and derivant thereof can act on the M phase of cell cycle, suppress cell mitogen, cause the nucleus textural anomaly and cause cell death.Dividing vigorous histiocyte is affected at first.This pharmacologically active of colchicine is used to treat tumor.On the tumor cell in vitro model, the cytostatic concentration of colchicine is that 0.5-1.3 μ M (0.2 μ g-0.6 μ g/ml) is (with reference to Reduction in S100 protein β subunit RNA in C6 rat glioma cells followingtreatment with anti-microtubular drugs.Robert Dunn, Charles Landry, David O ' Hanlon, James Dunn, Robert Allore, Ian Brown and Alexander Marks.The Journal of BiologicalChemistry.1987,262 (8): 3562-3566).On the experiment mice tumor model colchicine suppress the dosage of tumor be every day 1mg/kg (with reference to Evaluation of antivascular and antitumor effects of tubulin bindingagents in solid tumor therapy.Yukio Nihei, Manabu Suzuki, Akira Okano, Takashi Tsuji, Yukio Akiyama, Takashi Tsuruo, Sachiko Saito, Katsuyoshi Hori and Yasufumi Sato.Jpn.J.Cancer Res.1999,90:1387-1395).
At present, colchicine and derivant thereof are used to treat tumor and leukemia clinically, also are used for the treatment of acute gouty arthritis, diseases such as Cystic Fibrosis.Its therapeutic dose is: quiet, and each 1-2mg, the each 1mg of intravenous injection, once a day.Oral each 1mg.Quiet of colchicine derivative colchiceinamide or compound recipe colchiceinamide be 10mg once a day, oral each 5mg, every day 4 times.Untoward reaction is: oral administration can cause stomachache, diarrhoea, gastrointestinal reactions such as nausea and vomiting.Oral or intravenous administration can cause leukocyte and thrombocytopenia for a long time, and bone marrow depression and aplastic anemia, respiratory center suppress (with reference to modern clinical medicine grand ceremony, Luo Mingsheng, Gao Tianhui, Lao Jiahua chief editor, January calendar year 2001 front page, Sichuan science tech publishing house, 268-269 page or leaf; China's internal medicine, Chen Minzhang chief editor, People's Health Publisher, front page in 1999,3332-3333 page or leaf; Modern anti-tumor medicine is learned, Liao Zijun, Nan Kejun, Han Jun chief editor, Xi'an company of world book publishing house, front page in 2002,272-274 page or leaf).
Summary of the invention
The purpose of this invention is to provide a kind of tazettine and its derivant new medical use.
The present invention sets forth the pharmacologically active and the mechanism of action of colchicine and its derivant.Promoting promptly that the blood fibrinolytic system is active raises and promotes thromboembolism, thereby illustrates the various diseases that colchicine and derivant thereof can be used for treating and prevent to cause because of thrombosis in the blood vessel or thromboembolism.
The blood in human body in pipe comprises the tremulous pulse of all size diameter, and vein and blood capillary are under the normal physiological state, and tube chamber is open, and blood flow is unobstructed, with this nutrition and oxygen supply that guarantees each position internal organs of human body, keeps each position internal organs normal function running.Possesses a kind of clotting mechanism in the blood of human body, in case blood vessel wall occurs damaged, the activation of blood coagulation system, the Fibrinogen (fibrinogen) that finally causes solubility is converted into the fibrin (fibrin) of mutual linked network shape down in thrombin (thrombin) effect, at part generation blood coagulation.This physiology protection mechanism can prevent that loss of blood is too much, and helps the reparation of blood vessel wall.But under pathologic condition, blood vessel wall, especially directly the endothelial layer that contacts with blood can occur also can activating already contg thrombin and platelet in the blood unusually because of various factors.Its result causes Fibrinogen to be converted into fibrin, and is deposited on the blood vessel wall, thereby forms solid pathology thrombosis, causes the angiostenosis of diseased region, even stops up fully.In blood vessel, especially the thrombosis that forms in the vein with the blood flow walking, causes the blood vessel blockage in distal tubule chamber after can also coming off, and forms sudden thromboembolism.No matter be the formation of primary thrombus, or the sudden thromboembolism of far-end all can cause existing the internal organs blood of organizing at thrombosis position to supply blocking, cell death, infarction takes place in deterioration.The clinical typical disease that causes thus has myocardial infarction, and deep venous thrombosis and cerebral infarction are waited indefinitely.
Under normal circumstances can be removed behind the blood coagulation, to guarantee tissue repair by fibrinolysis mechanism.The fibrinolytic system that is grouped into by the Fibrinolytic various one-tenth of participation abbreviates fibrinolytic system as.Wherein most important composition be tissue plasminogen activator (tissue plasminogen activator, t-PA).T-PA is by the serine protease that is discharged into behind the vascular endothelial cell irriate in the blood, and the t-PA burst size has been controlled the speed of dissolving the thrombosis grumeleuse of being made up of fibrin.T-PA has highly affine fibrin, but not fibrinogenic biological nature, this characteristic has guaranteed that its effect has height locality and specificity.The t-PA that is adsorbed on the fibrin becomes fibrinolysin (plasmin) by transforming the plasminogen (plasminogen) that is adsorbed on equally on the fibrin, by fibrinolysin cutting thrombosis, the fibrin that makes mutual commissure is hydrolytic cleavage gradually, thereby removes thrombosis (with reference to the clinical new technique of thrombotic disease.Wang Hongli, Wang Xuefeng chief editor, January in 2003 the 1st edition, People's Medical Officer Press).
Therefore, thrombotic disease can be by pathologic promotion coagulation factor long-term existence, and is strong excessively, or the fibrinolytic system of human body is active crosses weak institute and cause.Therefore, the medicine that is used in the treatment thrombotic disease at present clinically is divided into two kinds, and a kind of passing through suppresses blood coagulation activity and antiplatelet aggregation, slows down thrombotic speed, represents medicine that heparin is arranged, vitamin K inhibitor and aspirin etc.Another kind of medicine is the fibrinolysis enhancing medicine, and by injecting a large amount of activator of plasminogens, the activation fibrinolysin is to reach the curative effect of quick thrombolytic.Represent medicine that recombiant protein t-PA is arranged.Other alternative medicine has streptokinase and urokinase.They are the bioprotein goods equally, by the activation plasminogen, reach thrombolytic purpose.But the general life-time service of last class medicine, the control thrombosis takes place and growth, then a class medicine generally when thrombosis causes that mortality is organized infarction the short time internal electronic monitoring use, reach the purpose of the life that gives emergency treatment to a patient.
The present invention's explanation, colchicine and derivant thereof can significantly improve vascular endothelial cell and discharge human body t-PA under the condition of low concentration, thereby promote thromboembolism to accelerate, therefore, colchicine and derivant thereof can be used for treating the various diseases that is caused by thromboembolism.
The present invention implements like this:
Materials and methods:
1.RT-PCR method is measured the expression of endothelial cell line tissue plasminogen activator
Human microvascular endothelial cell (mvec) is that the HMEC-1 cultivation after 48 hours, adds 5ng/ml respectively in the plate that contains the MCDB131 culture fluid that adds 10% calf serum; 2.5ng/ml, hatched 18 hours with the colchicine (Sigma company) of 0.5ng/ml, take off cell with trypsin, clean with phosphate buffer is centrifugal, extract the interior RNA always of cell.Do the expression that RT-PCR measures tissue plasminogen activator with following primer:
Primer 1:5 '-GTGTACACCAAGGTTACCAA-3 '
Primer 2: 5 '-GGAATACCTTCTGAGAGCCA-3 '
Do the expression that RT-PCR measures urokinase with following primer:
Primer 1:5 '-TCAAGTTCCATCGAACTGTG-3 '
Primer 2: 5 '-ATCAATGAAGCAGTGTGTGG-3 '
Above primer is ordered from Invitrogen company.
2. immune enzyme linked immunosorbent assay (ELISA) is measured the secretion colchicine of endothelial cell line tissue plasminogen activator:
Human microvascular endothelial cell (mvec) is that the HMEC-1 cultivation after 48 hours, adds 50ng/ml respectively in the plate that contains the MCDB131 culture fluid that adds 10% calf serum; 10ng/ml; 5ng/ml; The colchicine of 1ng/ml and 0.5ng/ml was hatched 24 hours, collected supernatant.Measure the concentration of tissue plasminogen activator in the supernatant samples with immune enzyme linked immunosorbent assay (test kit of American Diagnostic company).Cell is taken off counting with trypsin.Colchicine derivative:
Human microvascular endothelial cell (mvec) is that the HMEC-1 cultivation after 48 hours, adds 10ng/ml respectively in the plate that contains the MCDB131 culture fluid that adds 10% calf serum; 5ng/ml; 2.5ng/ml with the Demecolcine (Demecolcine, ICN company) of 1ng/ml, hatched 24 hours, collect supernatant.Measure the concentration of tissue plasminogen activator in the supernatant samples with immune enzyme linked immunosorbent assay (test kit of AmericanDiagnostic company).Cell is taken off counting with trypsin.
3. the active mensuration of tissue plasminogen activator in the laboratory animal blood plasma.
42 eight all big female C57BL/6 mices are divided into 7 groups, every group of 6 mices at random.Accept lumbar injection colchicine (being dissolved in normal saline) 40 μ g/kg respectively; 16 μ g/kg; 6.5 μ g/kg; 2.5 μ g/kg; 1 μ g/kg and 0.1 μ g/kg.Control mice is accepted the normal saline injection.Take a blood sample after 24 hours, with 3.8% sodium citrate anticoagulated whole blood, centrifugal (2500xg, 10 minutes) separate platelet poor plasma.The t-PA active concentration adopts mouse tissue activator of plasminogen active immne enzyme linked immunosorbent assay mensuration test kit (mouse t-PA activity ELISA assay kit) (Gentaur company) to measure in the blood plasma.Because that embedding is plasminogen activator inhibitor (PAI-1) on 96 orifice plates, have only free activated t-PA just possible in conjunction with onboard, so what measure is the t-PA active concentration.
4. tissue plasminogen activator's activity in the euglobulin method determination experiment animal blood slurry
25 16 all big female nude mices are divided into 5 groups, every group of 5 mices at random.Accept lumbar injection colchicine (being dissolved in normal saline) 40 μ g/kg respectively; 16 μ g/kg; 2.5 μ g/kg and 0.1 μ g/kg.Control mice is accepted the normal saline injection.Extract about 1ml blood sample by heart after 15 hours, with 3.8% sodium citrate anticoagulated whole blood, centrifugal (2500xg, 10 minutes) separate platelet poor plasma.(method is with reference to the modern pharmacology experimental technique to take the euglobulin clot lysis time method to measure in the blood plasma tissue plasminogen activator's activity.The Zhang Juntian chief editor, combined publication society of China Concord Medical Science University of Beijing Medical University, front page in 1998,1201 pages).
5. the molten observation of laboratory animal pulmonary infarction model bolt is (with reference to people's such as Stassen JM method: Stassen JM, Vanlinthout I, Lijnen HR and Collen D.A hamster pulmonary embolism model for thecvaluaton of the thrombolytic and pharmacokinetic properties of thrombolytic agents.Fibrinolysis, 1990 suppl 2,4:15-21 and Carmeliet P etc. are to the improvement of the method: Adenovirus-mediated transfer of tissue-type plasminogen activator augments thrombolysis in tissue-typeplasminogen activater-deficient and plasminogen activator-1-overexpressing mice.Blood, 1997,90 (4): 1527-1534).
125The preparation of the fibrin blood plasma grumeleuse of I labelling: use
125The Fibrinogen of I labelling, the mice platelet poor plasma (the same) of 3.8% sodium citrate anticoagulant preparation, and thrombin and CaCl
2Be mixed and made into.
21 ten all big female nude mices are divided into 3 groups, every group of 7 mices at random.Medication group mice is accepted lumbar injection colchicine (being dissolved in normal saline) 16 μ g/kg and 2.5 μ g/kg respectively, and control group mice is accepted the normal saline injection.After 12 hours, implement mouse anesthesia, with 25 μ l's
125The fibrin blood plasma grumeleuse of I labelling (contains and has an appointment 70000cpm's
125The human fibrinogen of I labelling and Mus blood plasma are mixed to be made) enter by the jugular vein injection and form pulmonary infarction in the body.The injection plasma clot placed the position, thoracic cavity to carry out pulmonary's isotope detection the gamma counter probe after 1 hour, as the molten preceding reference of bolt.The molten situation of continuous detecting bolt in the experimentation.Put to death mice after 16 hours, detect heart and the residual isotopic content of pulmonary.The isotopic mass of the isotopic mass contrast injection that disappears is as the molten percentage ratio of bolt.
6. colchicine is observed the toxicity of laboratory animal
24 seven all big female nude mices are divided into 3 groups, every group of 8 mices at random.Two groups of mices are accepted lumbar injection colchicine 40 μ g/kg and 16 μ g/kg every day, continuous 30 days respectively.Control group mice is accepted intraperitoneal injection of saline every day, continuous 30 days.Claimed a body weight in per two days.
Experimental result
1.RT-PCR experimental result shows that 5ng/ml and 2.5ng/ml colchicine can significantly increase the expression (Fig. 1) of endothelial cell tissue activator of plasminogen (t-PA).Under similarity condition, the expression of urokinase (u-PA) unaffected (Fig. 2).
2. immune enzyme linked immunosorbent assay experimental result shows, 50ng/ml, 10ng/ml, 5ng/ml and 1ng/ml colchicine can significantly increase the secretion (Fig. 3 A) of endothelial cell tissue activator of plasminogen (t-PA).In addition, observe used colchicine dosage in the experiment endotheliocyte is not had overt toxicity.10ng/ml; 5ng/ml and 2.5ng/ml Demecolcine also can significantly increase the secretion (Fig. 3 B) of endothelial cell tissue activator of plasminogen (t-PA).
3. colchicine significantly strengthens tissue plasminogen activator's activity in the laboratory animal blood plasma.Lumbar injection 6.5 μ g/kg and 2.5 μ g/kg colchicine can make tissue plasminogen activator's active concentration increase by 12 times and 16.8 times (Fig. 4) respectively in 24 hours.Euglobulin clot lysis time method result shows lumbar injection 40 μ g/kg, 16 μ g/kg; 2.5 μ g/kg and 0.1 μ g/kg colchicine after 15 hours the complete dissolution time of blood plasma euglobulin be respectively 108 ± 5 minutes, 55 ± 4 minutes, 37 ± 4 minutes and 110 ± 6 minutes, and matched group is 128 ± 5 minutes.
Table 1
| The injection natural law | Matched group body weight (g) | Inject 40 μ g/kg group body weight (g) | Inject 16 μ g/kg group body weight (g) |
| Zero day | 17.6±0.7 | 17.4±0.6 | 17.6±0.8 |
| Two days | 17.4±0.7 | 17.2±0.7 | 17.4±0.8 |
| Four days | 17.2±0.8 | 17.0±0.7 | 17.3±0.8 |
| Six days | 17.4±0.7 | 17.2±0.7 | 17.5±0.8 |
| Eight days | 18.7±0.7 | 18.5±0.7 | 18.7±0.8 |
| Ten days | 19.8±0.7 | 19.3±0.6 | 20.1±0.8 |
| 12 days | 20.5±0.9 | 20.2±0.7 | 20.6±0.7 |
| Fortnight | 21.7±0.7 | 21.2±0.6 | 21.9±0.8 |
| 16 days | 22.3±0.9 | 22.1±0.7 | 22.6±0.8 |
| 18 days | 22.8±0.9 | 22.4±0.7 | 23±0.9 |
| 20 days | 23.3±0.9 | 22.9±0.7 | 23.3±0.8 |
| 22 days | 23.9±0.7 | 23.5±0.8 | 24.1±0.7 |
| Two fortnights | 24.6±0.8 | 23.9±0.7 | 24.6±0.7 |
| 26 days | 25.1±0.9 | 24.7±0.9 | 25.2±0.9 |
| 28 days | 25.4±0.9 | 25.1±1.1 | 25.5±0.8 |
| 30 days | 26.9±1.2 | 26.4±1.3 | 27.1±0.9 |
4. colchicine accelerated tests animal pulmonary infarction dissolving.Lumbar injection colchicine 16 μ g/kg and 2.5 μ g/kg can cause 65% ± 7 and 87% ± 8 pulmonary infarction dissolving respectively after 16 hours.The control animals pulmonary infarction is dissolved as 32% ± 7 (Fig. 5).
5. continuous 30 day every day, lumbar injection colchicine 40 μ g/kg and 16 μ g/kg did not cause bleeding, and lost weight toxic reactions such as depilation and loss of appetite.Injection is the 30th day continuously, and the control group mice average weight is 26.9 ± 1.2g; Injection colchicine 40 μ g/kg group is 26.4 ± 1.3g; Injection colchicine 16 μ g/kg group is 27.1 ± 0.9g (table 1).
Experimental result shows that colchicine and derivant thereof can significantly strengthen the expression and the secretion of tissue plasminogen activator (t-PA) in quite low concentration range, thereby promotes fibrinolytic.And under similarity condition, the expression of urokinase (u-PA) is unaffected.Therefore the microdosage colchicine can be used for the treatment and the prevention of all thrombotic disease.
Colchicine and derivant or its pharmaceutically acceptable salt with the form of pharmaceutical composition separately or with materia medica on acceptable carrier or excipient, form compositions, compositions comprising but be not limited to low dose of aspirin, the compositions that Reopro etc. form.Pharmaceutically acceptable carrier refers to: one or more compatibility solids or liquid filling agent or excipient, they are suitable for the people uses, and enough purity and enough low toxicity must be arranged." compatibility " referred to herein as each component energy and chemical compound of the present invention and blending mutually between them in the compositions, and the drug effect of not obvious reduction chemical compound, medically acceptable carrier part example has sugar (as glucose, sucrose, lactose etc.) starch is (as corn starch, potato starch etc.) cellulose and common derivant thereof (are received as carboxylic formaldehyde cellulose, the acetaldehyde cellulose is received, cellulose ethanoate, the fine little element of little product) Polyethylene Glycol, gelatin, Pulvis Talci, stearic acid, magnesium stearate, calcium sulfate, vegetable oil (Oleum Glycines, Oleum sesami, Oleum Arachidis hypogaeae semen, the Fructus Canarii albi wet goods).It can also be chlorinating agent (as tween) wetting agent (as the dodecane sodium sulphate).The administering mode of chemical compound is depended in the selection of the carrier of compositions of the present invention.
Description of drawings
Fig. 1 is that RT-PCR measures endothelial cell tissue activator of plasminogen expression of results.
Cell is used 5ng/ml respectively; 2.5ng/ml and the colchicine of 0.5ng/ml is handled after 18 hours extraction RNA.Be RT-PCR with the t-PA special primer.The RT-PCR product is taken pictures through the agar plate electrophoresis, and tissue plasminogen activator's expression as shown in Figure 1.
Fig. 2 is that RT-PCR measures endotheliocyte urokinase expression of results.
Cell is used 5ng/ml respectively; 2.5ng/ml and the colchicine of 0.5ng/ml is handled after 18 hours extraction RNA.Be RT-PCR with the urokinase special primer.The RT-PCR product is taken pictures through the agar plate electrophoresis, and the urokinase expression as shown in Figure 2.
Fig. 3 is that immune enzyme linked immunosorbent assay is measured endothelial cell tissue activator of plasminogen secretion result.
Cell is used 50ng/ml respectively; 10ng/ml; 5ng/ml; The colchicine of 1ng/ml and 0.5ng/ml was handled after 24 hours, collected supernatant, measured the secretion of tissue plasminogen activator with immune enzyme linked immunosorbent assay.Counting cells.The concentration of tissue plasminogen activator is with per 10
6The t-PA secretory volume of individual cell is expressed among Fig. 3 A.
Cell is used 10ng/ml respectively; 5ng/ml; 2.5ng/ml; The Demecolcine of 1ng/ml was handled after 24 hours, collected supernatant, measured the secretion of tissue plasminogen activator with immune enzyme linked immunosorbent assay.Counting cells.The concentration of tissue plasminogen activator is with per 10
6The t-PA secretory volume of individual cell is expressed among Fig. 3 B.
Fig. 4 is the result of tissue plasminogen activator's active concentration in the immune enzyme linked immunosorbent assay determination experiment mice plasma.
Experiment mice is accepted lumbar injection colchicine (being dissolved in normal saline) 40 μ g/kg respectively; 16 μ g/kg; 6.5 μ g/kg; 2.5 μ g/kg; 1 μ g/kg and 0.1 μ g/kg.Take a blood sample after 24 hours, with 3.8% sodium citrate anticoagulated whole blood, centrifugal separation plasma.The active mouse tissue activator of plasminogen active immne enzyme linked immunosorbent assay mensuration test kit (mouse t-PA activity ELISA assay kit) (Gentaur company) that adopts of t-PA is measured in the blood plasma.The gained active concentration is the result show among Fig. 4.
Fig. 5 is the dissolved result of pulmonary infarction in the isotopic labeling body.Mice is accepted earlier lumbar injection colchicine (being dissolved in normal saline) 16 μ g/kg and 2.5 μ g/kg respectively.Anesthetized mice is incited somebody to action then
125The fibrin blood plasma grumeleuse of I labelling enters by the jugular vein injection and forms pulmonary embolism in the body.Put to death mice after 16 hours, detect heart and the residual isotopic content of pulmonary.The result is expressed among Fig. 5 after being converted into the molten percentage ratio of bolt.
Table 1 is the toxicity observed result of colchicine to laboratory animal.
Experiment mice is divided into 3 groups at random, every group of 8 mices.Two groups of mices are accepted lumbar injection colchicine 40 μ g/kg and 16 μ g/kg every day, continuous 30 days respectively.Control group mice is accepted intraperitoneal injection of saline every day.Claimed a body weight in per two days, the result lists table 1 in.
The specific embodiment
25 16 about 28 grams of all big female nude mice body weight are divided into 5 groups, every group of 5 mices at random.First group of mice accepted 1 property lumbar injection 40 μ g/kg colchicine (200 μ l are dissolved in normal saline, and concentration is 5.6 μ g/ml).Second group of mice accepted 1 property lumbar injection 16 μ g/kg colchicine (200 μ l are dissolved in normal saline, and concentration is 2.24 μ g/ml).The 3rd group of mice accepted 1 property lumbar injection 2.5 μ g/kg colchicine (200 μ l are dissolved in normal saline, and concentration is 0.35 μ g/ml).The 4th group of mice accepted 1 property lumbar injection 0.1 μ g/kg colchicine (200 μ l are dissolved in normal saline, and concentration is 0.014 μ g/ml).The 5th group of control mice accepted 1 property lumbar injection 200 μ l normal saline.Inject and use the Isofluran anesthetized mice after 15 hours, extract about 1ml blood sample, insert in the 1.5ml eppendorf centrifuge tube that contains 100 μ l3.8% sodium citrate by heart, mixing, room temperature centrifugal (2500xg, 10 minutes), separate platelet poor plasma, each get 0.55ml blood plasma approximately.Get 0.5ml blood plasma, take the euglobulin clot lysis time method to measure tissue plasminogen activator's activity in the blood plasma." modern pharmacology experimental technique " 1201 pages of described carrying out that concrete operations are edited according to Zhang Juntian fully.Experimental result shows lumbar injection 40 μ g/kg; 16 μ g/kg; 2.5 μ g/kg and 0.1 μ g/kg colchicine are respectively organized the complete dissolution time of mice plasma euglobulin and on average were respectively 108 ± 5 minutes after 15 hours, and 55 ± 4 minutes, 37 ± 4 minutes and 110 ± 6 minutes, and matched group is 128 ± 5 minutes.
Embodiment 2
The mixed mice platelet poor plasma of 3.8% sodium citrate anticoagulant preparation: 2 eight all big female nude mices are anaesthetized with Isofluran, extract about 1ml blood sample by heart, insert in the 1.5mleppendorf centrifuge tube that contains 100 μ l, 3.8% sodium citrate, mixing, centrifugal (the 2500xg of room temperature, 10 minutes), separate platelet poor plasma, the blood plasma of 2 mices of gained is mixed evenly standby.
125The human fibrinogen of I labelling: provide by Amersham company, be diluted to 70000cpm/ μ l with normal saline.
125The preparation of the fibrin blood plasma grumeleuse of I labelling: in the eppendorf of 0.5ml pipe, add the above-mentioned mice plasma of 21 μ l respectively, 1 μ l 70000cpm's
125The human fibrinogen of I labelling, and the 1M CaCl of the thrombin of the 0.07UI/ μ l of 0.5 μ l and 2.4 μ l
2Mix, and be drawn into immediately in the conduit of 6FG, place 37 ℃ to hatch 30 minutes, treat that grumeleuse forms the back room temperature and places standby.
21 ten about 20 grams of all big female nude mice body weight are divided into 3 groups, every group of 7 mices at random.First group of mice accepted disposable celiac and injects 16 μ g/kg colchicine (200 μ l, be dissolved in normal saline, concentration is 1.6 μ g/ml), second group of mice accepted disposable celiac injection colchicine 2.5 μ g/kg (200 μ l, be dissolved in normal saline, concentration is 0.25 μ g/ml), the 3rd group of control mice accepted disposable 200 μ l normal saline lumbar injections.With mouse anesthesia, jugular vein is exposed after 12 hours, will contain 25 μ l's
125The conduit of the fibrin blood plasma grumeleuse of I labelling is introduced in the jugular vein, the thromboembolism injection is entered form pulmonary infarction in the body.Change the heparin solution of tube injection 0.1ml (300U/ml) then.The injection plasma clot placed the position, thoracic cavity to carry out pulmonary's isotope detection the gamma counter probe after 1 hour, as the molten preceding reference of bolt.Put to death mice after 16 hours, detect heart and the residual isotopic content of pulmonary.The isotopic mass of the isotopic mass contrast injection that disappears is as the molten percentage ratio of bolt.Experimental result is seen Fig. 5.
Embodiment 3
42 eight about 18 grams of all big female C57BL/6 mice body weight are divided into 7 groups, every group of 6 mices at random.Accept disposable celiac respectively and inject 200 μ l colchicine solutions (being dissolved in normal saline).Inject 40 μ g/kg (concentration is 3.6 μ g/ml) for first group; Inject 16 μ g/kg (concentration is 1.45 μ g/ml) for second group; Inject 6.5 μ g/kg (concentration is 0.6 μ g/ml) for the 3rd group; Inject 2.5 μ g/kg (concentration is 0.225 μ g/ml) for the 4th group; Inject 1 μ g/kg (concentration is 0.09 μ g/ml) for the 5th group; Inject 0.1 μ g/kg (concentration is 0.009 μ g/ml) for the 6th group.The 7th group of control mice accepted the injection of 200 μ l normal saline.Extract about 200 μ l blood samples by the eye socket vein after 24 hours, as described in embodiment 1, with 3.8% sodium citrate anticoagulated whole blood, centrifugal (2500xg, 10 minutes) separate platelet poor plasma.The t-PA active concentration adopts mouse tissue activator of plasminogen active immne enzyme linked immunosorbent assay mensuration test kit (mouse t-PA activityELISA assay kit) (Gentaur company) to measure in the blood plasma.Concrete operations are fully according to the test kit requirement.Experimental result is seen Fig. 4.
Claims (5)
1, the medical usage of following colchicine of a kind of structural formula and its derivant is used in preparation prevention, treatment are caused the medicine of thrombotic disease by thrombosis or thromboembolism
2, the medical usage of colchicine according to claim 1 and its derivant is characterized in that comprising in myocardial infarction, deep venous thrombosis and cerebral infarction, cerebral thrombosis, the medicine at the thrombotic disease that preparation prevention, treatment are caused by thrombosis or thromboembolism and uses.
3, the medical usage of colchicine according to claim 1 and its derivant, it is characterized in that comprising low-dosage aspirin in the compositions that preparation is made up of colchicine and its derivant, low molecular weight heparin, Reopro and medically acceptable carrier are used in the medicine of excipient.
4, the medical usage of colchicine according to claim 3 and its derivant is characterized in that colchicine and its derivant and pharmaceutically acceptable vehicle excipients make tablet, injection or other dosage form.
5, the medical usage of colchicine according to claim 3 and its derivant, comprise colchicine and its derivant as main active, the medicine or the health promoting product of thrombotic disease that auxiliary activity composition or adding ingredient, preparation prevention, treatment are caused by thrombosis or thromboembolism and the disease relevant with thrombosis or thromboembolism.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510030151 CN1939290A (en) | 2005-09-29 | 2005-09-29 | Medical usage of colchicine and its derivative |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510030151 CN1939290A (en) | 2005-09-29 | 2005-09-29 | Medical usage of colchicine and its derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1939290A true CN1939290A (en) | 2007-04-04 |
Family
ID=37957999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510030151 Pending CN1939290A (en) | 2005-09-29 | 2005-09-29 | Medical usage of colchicine and its derivative |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1939290A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150196514A1 (en) * | 2012-11-02 | 2015-07-16 | Murray And Poole Enterprises Limited | Method of treating cardiovascular events using colchicine concurrently with an antithrombotic drug |
| US10105319B2 (en) | 2013-04-16 | 2018-10-23 | Murray And Poole Enterprises Limited | Sustained-release formulations of colchicine and methods of using same |
| CN109125308A (en) * | 2018-08-17 | 2019-01-04 | 上海市浦东新区浦南医院 | Colchicin is in the new application for preventing and treating ischemic cerebrovascular disease |
-
2005
- 2005-09-29 CN CN 200510030151 patent/CN1939290A/en active Pending
Cited By (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10842761B2 (en) | 2012-11-02 | 2020-11-24 | Murray And Poole Enterprises Ltd | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
| US11666545B2 (en) | 2012-11-02 | 2023-06-06 | Murray And Poole Enterprises Ltd | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
| JP2015535264A (en) * | 2012-11-02 | 2015-12-10 | マレイ・アンド・プール・エンタープライゼズ・リミテッド | Treatment or prevention of cardiovascular events by administration of colchicine derivatives |
| EP2914255A4 (en) * | 2012-11-02 | 2016-06-29 | Murray & Poole Entpr Ltd | TREATMENT OR PREVENTION OF CARDIOVASCULAR EVENTS BY ADMINISTRATION OF A COLCHICINE DERIVATIVE |
| US9744144B2 (en) | 2012-11-02 | 2017-08-29 | Murray And Poole Enterprises Limited | Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent |
| CN104918613B (en) * | 2012-11-02 | 2018-05-25 | 默里和普尔企业有限公司 | Treatment or prevention of cardiovascular events by administration of colchicine derivatives |
| KR102858016B1 (en) | 2012-11-02 | 2025-09-11 | 머레이 앤 풀 엔터프라이지즈, 리미티드 | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
| CN108721265A (en) * | 2012-11-02 | 2018-11-02 | 默里和普尔企业有限公司 | Cardiovascular event is treated or prevented by giving colchicine derivative |
| US12364675B2 (en) | 2012-11-02 | 2025-07-22 | Murray And Poole Enterprises Ltd | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
| US12280025B2 (en) | 2012-11-02 | 2025-04-22 | Murray And Poole Enterprises Ltd | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
| US10206891B2 (en) | 2012-11-02 | 2019-02-19 | Murray And Poole Enterprises Ltd | Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent |
| US10265281B2 (en) | 2012-11-02 | 2019-04-23 | Murray And Poole Enterprises Ltd | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
| US12233035B2 (en) | 2012-11-02 | 2025-02-25 | Murray And Poole Enterprises Ltd | Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent and statin |
| US10842762B2 (en) | 2012-11-02 | 2020-11-24 | Murray And Poole Enterprises Ltd | Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent |
| CN104918613A (en) * | 2012-11-02 | 2015-09-16 | 默里和普尔企业有限公司 | Treatment or prevention of cardiovascular events by administration of colchicine derivatives |
| US11026900B2 (en) | 2012-11-02 | 2021-06-08 | Murray And Poole Enterprises Ltd | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
| EP3964205A1 (en) * | 2012-11-02 | 2022-03-09 | Murray & Poole Enterprises, Ltd | Treatment or prevention of cardiovascular events |
| US11026901B2 (en) | 2012-11-02 | 2021-06-08 | Murray And Poole Enterprises Ltd | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
| US11026899B2 (en) | 2012-11-02 | 2021-06-08 | Murray And Poole Enterprises Ltd | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
| CN108721265B (en) * | 2012-11-02 | 2022-12-02 | 默里和普尔企业有限公司 | Treatment or prevention of cardiovascular events by administration of colchicine derivatives |
| KR20230049751A (en) * | 2012-11-02 | 2023-04-13 | 머레이 앤 풀 엔터프라이지즈, 리미티드 | Treatment or prevention of cardiovascular events via the administration of a colchicine derivativ |
| KR20240074883A (en) * | 2012-11-02 | 2024-05-28 | 머레이 앤 풀 엔터프라이지즈, 리미티드 | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
| US20150196514A1 (en) * | 2012-11-02 | 2015-07-16 | Murray And Poole Enterprises Limited | Method of treating cardiovascular events using colchicine concurrently with an antithrombotic drug |
| US11944595B2 (en) | 2012-11-02 | 2024-04-02 | Murray And Poole Enterprises Ltd | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
| US11944594B2 (en) | 2012-11-02 | 2024-04-02 | Murray And Poole Enterprises Ltd | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
| KR102666548B1 (en) | 2012-11-02 | 2024-05-21 | 머레이 앤 풀 엔터프라이지즈, 리미티드 | Treatment or prevention of cardiovascular events via the administration of a colchicine derivativ |
| US11648206B2 (en) | 2013-04-16 | 2023-05-16 | Murray And Poole Enterprises Ltd | Sustained-release formulations of colchicine and methods of using same |
| US10610488B2 (en) | 2013-04-16 | 2020-04-07 | Murray & Poole Enterprises, Ltd. | Sustained-release formulations of colchicine and methods of using same |
| US10130585B2 (en) | 2013-04-16 | 2018-11-20 | Murray And Poole Enterprises Limited | Methods of treating and/or preventing cardiovascular disease |
| US10105319B2 (en) | 2013-04-16 | 2018-10-23 | Murray And Poole Enterprises Limited | Sustained-release formulations of colchicine and methods of using same |
| CN109125308A (en) * | 2018-08-17 | 2019-01-04 | 上海市浦东新区浦南医院 | Colchicin is in the new application for preventing and treating ischemic cerebrovascular disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Palladino Jr et al. | Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity. | |
| Mueller et al. | History of drugs for thrombotic disease. Discovery, development, and directions for the future. | |
| Martin | Cell death and inflammation: the case for IL‐1 family cytokines as the canonical DAMP s of the immune system | |
| CN107405391B (en) | Systemic and topical application of platelet microparticles for the treatment of bleeding in trauma patients | |
| Ogawa | Mechanisms of the development of organ failure following surgical insult: the'second attack'theory | |
| CN1371287A (en) | Preserved pharmaceutical formulations | |
| TW201313236A (en) | Pharmaceutical composition for inhibiting inflammation | |
| Hashemibeni et al. | Comparison of the efficacy of piascledine and transforming growth factor β1 on chondrogenic differentiation of human adipose-derived stem cells in fibrin and fibrin-alginate scaffolds | |
| JP2820699B2 (en) | Thrombolytic agent | |
| Bachmann | Disseminated intravascular coagulation | |
| US20240399032A1 (en) | Hydrogel for promoting growth of mesenchymal stem cells, and preparation method and application method thereof | |
| Dubber et al. | In vitro and in vivo studies with Trasylol, an anticoagulant and a fibrinolytic inhibitor | |
| CN1939290A (en) | Medical usage of colchicine and its derivative | |
| CN101229369A (en) | Antiatheroscloresis thrombolytic soft capsule and preparing method thereof | |
| CN106974896A (en) | A kind of antitumor agent containing hydrophobicity chemotherapeutics nano particle and Fibrin Glue | |
| CN101926985A (en) | Lumbrokinase injection for treating thromboembolic disease | |
| CN114073758A (en) | Application of compound Isaridin E or its medicinal salt in the preparation of antithrombotic medicine | |
| JP2002371006A (en) | Agent for preventing and / or preventing progression of pulmonary fibrosis | |
| Schapira et al. | Severe myalgia in familial Mediterranean fever: clinical and ultrastructural aspects. | |
| CN1663610A (en) | Lysozyme preparation | |
| CN106822862B (en) | Application of polypeptide modified nanoparticles in preparation of medicine for treating acute lung injury | |
| CN115300516A (en) | Medicinal composition for treating rheumatoid arthritis and application thereof | |
| CN100391535C (en) | Application of enzymic hemostat in antagonizing hirudin hemorrhage | |
| Goubran et al. | Coagulation and Anticoagulants | |
| CN1064241C (en) | Snake poison anti-cancer medicine and its prepn. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20070404 |